Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lebwohl

Showing results (311-320 of 418) with videos related to

Pageof 42
Sort By:
The Journal of Investigative Dermatology|September 7, 2025
Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and PolicyJoshua Burshtein, Christopher G Bunick, Ruth Ann Vleugels, et al.
The British Journal of Dermatology|January 25, 2025
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension periodRichard B Warren, Mark Lebwohl, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
Journal of the American Academy of Dermatology|December 25, 2019
Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathwaysMichelle S Min, Jianni Wu, Helen He, et al.
Dermatology and Therapy|March 7, 2024
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical TrialsRui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, et al.
Dermatology and Therapy|December 8, 2025
Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHTApril Armstrong, Kim A Papp, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.
Dermatology and Therapy|March 21, 2025
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis TrialsApril W Armstrong, Leon Kircik, Linda Stein Gold, et al.
Dermatology and Therapy|May 30, 2023
Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)Paolo Gisondi, Alice B Gottlieb, Boni Elewski, et al.
Dermatology Online Journal|October 31, 2025
A review of the safety, efficacy, and administration of hedgehog inhibitors for the treatment of advanced basal cell carcinoma: an expert consensus panelMilaan Shah, Lauren Debusk, Angela Rosenberg, et al.
Pageof 42

Showing results (311-320 of 418) with videos related to

Sort By:
Pageof 42
The Journal of Investigative Dermatology|September 7, 2025
Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and PolicyJoshua Burshtein, Christopher G Bunick, Ruth Ann Vleugels, et al.
The British Journal of Dermatology|January 25, 2025
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension periodRichard B Warren, Mark Lebwohl, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
Journal of the American Academy of Dermatology|December 25, 2019
Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathwaysMichelle S Min, Jianni Wu, Helen He, et al.
Dermatology and Therapy|March 7, 2024
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical TrialsRui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, et al.
Dermatology and Therapy|December 8, 2025
Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHTApril Armstrong, Kim A Papp, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.
Dermatology and Therapy|March 21, 2025
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis TrialsApril W Armstrong, Leon Kircik, Linda Stein Gold, et al.
Dermatology and Therapy|May 30, 2023
Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)Paolo Gisondi, Alice B Gottlieb, Boni Elewski, et al.
Dermatology Online Journal|October 31, 2025
A review of the safety, efficacy, and administration of hedgehog inhibitors for the treatment of advanced basal cell carcinoma: an expert consensus panelMilaan Shah, Lauren Debusk, Angela Rosenberg, et al.
Pageof 42